Virus inactivation in the 1990s - And into the 21st century: Part 3b, plasma and plasma products (treatments other than heat or solvent/detergent)

BioPharm

Volumn 15, Issue 10, 2002, Pages 42-49+51

  Sofer, Gail ^a  

^a BioReliance   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3,3' (1,4 NAPHTHYLIDENE)DIPROPIONATE; CHLORINE DERIVATIVE; IODINE; OCTANOIC ACID; PEPSIN A; PROPIOLACTONE; PROPIONIC ACID; PSORALEN; SULFONIC ACID DERIVATIVE; UNCLASSIFIED DRUG;

DRUG INDUSTRY; DRUG MANUFACTURE; GAMMA IRRADIATION; HUMAN IMMUNODEFICIENCY VIRUS 1; HYDROSTATIC PRESSURE; PH; PHOTOTHERAPY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; ULTRAVIOLET IRRADIATION; VIRUS INACTIVATION;

EID: 0036794218     PISSN: 10408304     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (43)

1. Sofer G., "Virus Inactivation in the 1990s - and into the 21st Century: Skin, Bone, and Cells," BioPharm 15(7) 18-24 (July 2002).
2. Sofer G., "Virus Inactivation in the 1990s - and into the 21st Century: Red Blood Cells and Platelets," BioPharm 15(8) 42-49 (August 2002).
3. Sofer G., "Virus Inactivation in the 1990s - and into the 21st Century: Part 3a, Plasma and Plasma Products (Heat and Solvent/Detergent Treatments)," BioPharm 15(9) 28-42 (September 2002).
4. Abe H. et al., "Elimination of Both Cell-Free and Cell-Associated HIV Infectivity in Plasma by a Filtration/Methylene Blue Photoinactivation System," Transfusion 40(9), 1081-1087 (September 2000).
5. Mohr H., "Inactivation of Viruses in Human Plasma Methods," Enzymol. 319, 207-216 (2000).
6. Mohr H., Lambrecht B., and Schmitt H., "Photo-Inactivation of Viruses in Therapeutical Plasma," Dev. Biol. Stand. 81, 177-183 (1993).
7. Lambrecht B. et al., "Rapid Inactivation of HIV-1 in Single Donor Preparations of Human Fresh, Frozen Plasma by Methylene Blue/Light Treatment," Biologicals 22(3), 227-231 (September 1994).
8. Muller-Breitkreutz K. and Mohr H., "Hepatitis C and Human Immunodeficiency Virus RNA Degradation by Methylene Blue/Light Treatment of Human Plasma," J. Med. Virol. 56(3), 239-245 (November 1998).
9. Muller-Breitkreutz K. et al., "Inactivation of Viruses by Chemically and Photochemically Generated Singlet Molecular Oxygen," J. Photochem. Photobiol. B 30(1), 63-70 (September 1995).
10. Bachmann B. et al., "Target Structures for HIV-1 Inactivation by Methylene Blue and Light," J. Med. Virol. 47(2), 172-178 (October 1995).
11. Mohr H., Lambrecht, B., and Selz A., "Photodynamic Virus Inactivation of Blood Components Immunological Investigations," Immunol. Invest. 24(1,2), 73-85 (1995).
12. Lambrecht B. et al, "Photoinactivation of Viruses in Human Fresh Plasma by Phenothiazine Dyes in Combination with Visible Light," Vox Sang. 60, 207-213 (1991).
13. Ben-Hur E. and Horowitz B., "Advances in Photochemical Approaches for Blood Sterilization," Photochem. Photobiol. 62, 383-388 (1995).
14. Lynch T., "New Technologies for Viral Inactivation," paper presented at IBC Biological Safety and Production conference, 2-5 April 2001, Tysons Corner, VA.
15. Hornsey V.S. et al., "Potentially Improved Approach to Methylene Blue Virus Inactivation of Plasma: The Maco Pharma Maco-Tronic System," Transfus. Med. 11(1), 31-36 (2001).
16. Grandadam M. et al., "Photodynamic Inactivation of Cell-Free HIV Strains by a Red-Absorbing Chlorin-Type Photosensitizer," J. Photochem. Photobiol. B 31(3), 171-177 (December 1995).
17. Morel P. et al., "Photochemical Inactivation of Viruses and Bacteriophage in Plasma and Plasma Fractions," Blood Cells 18(1), 27-41, 41-42 (1992).
18. Dichtelmuller H. et al., "Validation of Virus Inactivation and Removal for the Manufacturing Procedure of Two Immunoglobulins and a 5% Serum Protein Solution Treated with Beta-Propiolactone," Biologicals 21(3), 259-268 (September 1993).
19. Lawrence S.A., "Beta-Propiolactone: Viral Inactivation in Vaccines and Plasma Products," PDA J. Pharm. Sci. Technol. 54(3), 209-217 (May-June 2000).
20. Scheidler A., "Inactivation of Viruses by Beta-Propiolactone in Human Cryo-Poor Plasma and IGG Concentrates," Biologicals 26(2), 135-144 (June 1998).
21. Norley S.G., Lower J., and Kurth R., "Insufficient Inactivation of HIV-1 in Human Cryo Poor Plasma by Beta-Propiolactone: Results from a Highly Accurate Virus Detection Method," Biologicals 21(3), 251-258 (September 1993).
22. Epstein J.S. and Fricke W.A., "Current Safety of Clotting Factor Concentrates," Arch. Pathol. Lab. Med. 114(3), 335-340, and comments (March 1990).
23. Nowak T. et al., "Virus Safety of Human Immunoglobulins: Efficient Inactivation of Hepatitis C and Other Human Pathogenic Viruses by the Manufacturing Procedure," J. Med. Virol. 36(3), 209-216 (March 1992).
24. Hilfenhaus J.W. et al., "Inactivation of HIV-1 and HIV-2 by Various Manufacturing Procedures for Human Plasma Proteins," Cancer Detect. Prev. 14(3), 369-375 (1990).
25. Bradley D.W. et al., "Pressure Cycling Technology: A Novel Approach to Virus Inactivation in Plasma," Transfusion 40(2), 193-200 (February 2000).
26. Miekka S.I. et al., "New Methods for Inactivation of Lipid-Enveloped and Nonenveloped Viruses," Haemophilia 4(4), 402-408 (July 1998).
27. Highsmith F. et al., "Iodine-Mediated Inactivation of Lipid- and Non-Lipid-Enveloped Viruses in Human Antithrombin III Concentrate," Blood 86(2), 791-796 (15 July 1995).
28. Highsmith F.A. et al., "Inactivation of Lipid-Enveloped and Non-Lipid-Enveloped Model Viruses in Normal Human Plasma by Crosslinked Starch-Iodine," Transfusion 34(4), 322-327 (April 1994).
29. Highsmith F.A. et al., "Viral Inactivation of Vesicular Stomatitis Virus in Normal Human Serum by Cross-Linked Polyvinylpyrrolidone," J. Infect. Dis. 167(5), 1027-1033 (May 1993).
30. Skladanek M., "Viral Inactivation Utilizing Depth Filter Media Containing a PVPP-Iodine Complex," paper presented at the PDA-FDA Viral Clearance Forum, 1-3 October 2001, Bethesda, MD.
31. Lundblad J.I. and Seng R.I., "Inactivation of Lipid-Enveloped Viruses in Proteins by Caprylate," Vox Sang. 60(2), 75-81 (1991).
32. Korneyeva M. et al., "Enveloped Virus Inactivation by Caprylate: A Robust Alternative to Solvent/Detergent Treatment," paper presented at the PDA-FDA Viral Clearance Forum, 1-3 October 2001, Bethesda, MD.
33. Marx G. et al., "Protecting Fibrinogen with Rutin During UVC Irradiation for Viral Inactivation," Photochem. Photobiol. 63(4), 541-546 (April 1996).
34. Chin S. et al., "Virucidal Short Wavelength Ultraviolet Light Treatment of Plasma and Factor VIII Concentrate: Protection of Proteins by Antioxidants," Blood 86(11), 4331-4336 (December 1995).
35. Hart H., Reid K., and Hart W., "Inactivation of Viruses During Ultraviolet Light Treatment of Human Intravenous Immunoglobulin and Albumin," Vox Sang. 64(2), 82-88 (1993).
36. Sugawara H. et al., "Inactivation of Parvovirus B 19 in Coagulation Factor Concentrates by UVC Radiation: Assessment of an In Vitro Infectivity Assay Using CFU-E Derived from Peripheral Blood CD34+ Cells," Transfusion 41(4), 456-461 (2001).
37. Cover W.H., "Validation of Broad Spectrum Pulsed Light as a Virus Inactivation Step," paper presented at the PDA-FDA Viral Clearance Forum, 1-3 October 2001, Bethesda, MD.
38. Hiemstra H. et al., "Inactivation of Human Immunodeficiency Virus by Gamma Radiation and its Effect on Plasma and Coagulation Factors," Transfusion 31(1), 32-39 (January 1991).
39. Omar A. et al., "Virus Inactivation by Pepsin Treatment at pH 4 of IgG Solutions: Factors Affecting the Rate of Virus Inactivation," Transfusion 36(10), 866-872 (October 1996).
40. Hamalainen E., Suomela H., and Ukkonen P., "Virus Inactivation During Intravenous Immunoglobulin Production," Vox Sang. 63(1), 6-11 (1992).
41. Kempf C. et al., "Virus Inactivation During Production of Intravenous Immunoglobulin," Transfusion 31(5), 423-427 (June 1991).
42. Kempf C. et al., "Inactivation of Human Immunodeficiency Virus (HIV) by Low pH and Pepsin," J. Acquir. Immune. Defic. Syndr. 4(8), 828-830 (1991).
43. Louie R.E. et al., "Inactivation of Hepatitis C Virus in Low pH Intravenous Immunoglobulin," Biologicals 22(1), 13-19 (March 1994).